Odiparcil

Odiparcil (SB-424323) is an orally active β-D-xyloside derivative. Odiparcil can effectively divert the synthesis of cellular glycosaminoglycans (GAG) into secreted soluble species and reduce GAG accumulation. Odiparcil shows antithrombin and antiplatelet activity. Odiparcil can be used for the researches of metabolic and cardiovascular disease, such as mucopolysaccharidoses (MPS) and thrombosis[1][2].

Product Specifications

CAS Number

[137215-12-4]

Product Name Alternative

SB-424323

UNSPSC

12352005

Target

Thrombin

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Neuroscience-Neuromodulation

Field of Research

Metabolic Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/odiparcil.html

Purity

99.98

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CC(C1=CC=C(O[C@H]2[C@@H]([C@H]([C@@H](CS2)O)O)O)C=C1O3)=CC3=O

Molecular Formula

C15H16O6S

Molecular Weight

324.35

References & Citations

[1]Entchev E, et al. Odiparcil, a potential glycosaminoglycans clearance therapy in mucopolysaccharidosis VI-Evidence from in vitro and in vivo models. PLoS One. 2020 May 15;15 (5) :e0233032.|[2]Toomey JR, et al. A comparison of the beta-D-xyloside, odiparcil, to warfarin in a rat model of venous thrombosis. J Thromb Haemost. 2006 Sep;4 (9) :1989-96.